Kardigan raises $400.0M IPO (United States, Jun 2026)
Find the investors funding Health IPO rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
Kardigan extends biotech’s streak of big IPOs with $400M haul - BioPharma Dive
Kardigan is a cardiovascular drug startup focused on developing innovative treatments for heart conditions. The company has raised significant funding through both private venture capital and an initial public offering, highlighting its rapid growth and the increasing interest in biotech investments. Its lead drug, danicamtiv, is in late-stage testing for dilated cardiomyopathy, a condition currently lacking approved treatments.
Kardigan extends biotech’s streak of big IPOs with $400M haul BioPharma Dive
| Oct 02, 2026 | Supabase | $150.0M | Growth Equity | United States |
| Oct 02, 2026 | SoLa Impact | $93.0M | Debt | United States |
| Oct 02, 2026 | FieldAI | $700.0M | — | United States |
| Oct 02, 2026 | CScale | $145.0M | Series C | United States |
21,706 investors back startups in United States
You just read who funded Kardigan. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.